ORIC:NASDAQOric Pharmaceuticals, Inc. Analysis
Data as of 2026-08-10 - not real-time
$13.50
Latest Price
9/10Risk
Risk Level: High
Executive Summary
ORIC Pharmaceuticals, Inc. trades at $13.50, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it gained 42.7%. RSI sits at 66.4, which reads as approaching overbought, and MACD momentum is bullish. The recent range runs from support at $10.30 up to resistance at $14.05.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 54.4% above the current quote.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 94.0%, a beta of 1.49 and a maximum drawdown of 48.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 54.4% above the current quote.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 94.0%, a beta of 1.49 and a maximum drawdown of 48.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top Market Events
When a stock experiences a golden cross technical event, good things could be on the horizon.Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLCEnozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading above the 200-day average of 10.57
- MACD momentum is positive
- 30-day price change of +42.7%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading above the 200-day average of 10.57
- Analyst targets imply +54.4% versus the current price
- 30-day volatility of 94.0%
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +54.4% versus the current price
- Negative return on equity of -39.8%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-8.3
ROE-39.80%
ROA-25.97%
Debt/Equity1.57
P/B Ratio3.7
Op. Cash Flow$-111638000
Free Cash Flow$-68834624
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI66.4
Support$10.30
Resistance$14.05
MA 20$11.50
MA 50$10.08
MA 200$10.57
MACDBullish
VolumeIncreasing
Fear & Greed Index93.82
Valuation
Target Price$20.85
Upside/Downside54.42%
GradeFair
TypeBlend
Risk Assessment
Beta1.49
Volatility93.98%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.